Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS 4th of July Sale! 15% Discount with Code:
DNRSRECOVERY

Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

The efficacy of treatments for irritable bowel syndrome

 

 

 

 

Aliment Pharmacol Ther. 2006 Jul 15;24(2):183-205.

 

Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective.

 

Tack J, Fried M, Houghton LA, Spicak J, Fisher G. University Hospital of Leuven, Leuven, Belgium.

 

Irritable bowel syndrome (IBS) is a common, chronic disorder, characterized by abdominal pain/discomfort, bloating and altered bowel habit. To conduct a systematic evidence-based review of pharmacological therapies currently used, or in clinical development, for the treatment of IBS in Europe. The safety and tolerability of these therapies are the subject of an accompanying review. A literature search was completed for randomized controlled studies which included adult patients with IBS and an active or placebo control, assessed IBS symptoms, and were published in English between January 1980 and June 2005. The level of evidence for efficacy was graded according to the quality of the trial design and the study outcome. There is some evidence for improvement of individual IBS symptoms with antidiarrhoeals (diarrhoea), antispasmodics (abdominal pain/discomfort), bulking agents (constipation), tricyclic antidepressants (abdominal pain/discomfort) and behavioural therapy. In contrast, there is strong evidence for the improvement of global IBS symptoms with two new serotonergic agents: the 5-HT(4) selective agonist tegaserod (IBS with constipation) and the 5-HT(3) antagonist alosetron (IBS with diarrhoea). Further data are required for the 5-HT(3) antagonist, cilansetron, and the mixed 5-HT(3)antagonist/5-HT(4) agonist renzapride before their utility in IBS can be appraised. There is limited evidence for the efficacy, safety and tolerability of therapies currently available in Europe for the treatment of IBS. Overall, there is an absence of pharmacological agents licensed specifically for the treatment of IBS subtypes, and new agents are awaited in Europe that will allow changes in clinical practice to focus on and improve global IBS symptoms.

 

PMID: 16842448 [PubMed - in process]

 

Full Article Available Online

 

 

 

{mosgoogle}

 

{mos_sb_discuss:11}

 


 

 

Related Articles:

 

Mold Testing & Sanitizer:

 

 

 

 

ADVERTISEMENT

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner